What this means
This trial is still recruiting people and has posted no results yet. It tests whether a pill called NMN may slow aging and whether it is safe to take by mouth.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 39–70
- Where
- 1 site
The science
- Registered title
- Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
- Trial ID
- NCT06592859 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging, NMN
- What is tested
- NMN, placebo
- Sponsor
- People's Hospital of Quzhou
- Ages
- 39 Years to 70 Years
- Dates
- First posted Sep 19, 2024 · updated May 8, 2026
Registry summary
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Sites (1)
- People's Hospital of Quzhou, Quzhou, Zhejiang, China